The carcinogenic potential of tacrolimus ointment beyond immune suppression: A hypothesis creating case report

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Becker, Jürgen C ^a   Houben, Roland ^a   Vetter, Claudia S ^a   Bröcker, Eva B ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; CALCIUM ANTAGONIST; DAPSONE; DEXAMETHASONE; ETRETIN; LIPID; MITOGEN ACTIVATED PROTEIN KINASE; MOMETASONE FUROATE; PROTEIN P53; TACROLIMUS;

ADULT; ANAMNESIS; ARTICLE; BURNING SENSATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CARCINOGENICITY; CASE REPORT; CLINICAL FEATURE; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; ERYTHEMA; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE DEFICIENCY; LICHEN PLANUS; MALIGNANT TRANSFORMATION; MOUTH CANCER; OINTMENT; ORAL BIOPSY; PRURITUS; RECURRENT DISEASE; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ADMINISTRATION, TOPICAL; CALCINEURIN; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; FEMALE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LICHEN PLANUS, ORAL; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 3; TACROLIMUS; TONGUE NEOPLASMS;

EID: 33646154439     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-7     Document Type: Article

References (24)

1. Nghiem P, Pearson G, Langley RG: Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002, 46:228-241.
2. Nakagawa H, Etoh T, Ishibashi Y, Higaki Y, Kawashima M, Torii H, Harada S: Tacrolimus ointment for atopic dermatitis. Lancet 1994, 344:883.
3. US FDA advisory committee recommends approval of tacrolimus ointment. Skin Therapy Lett 2000, 6:5.
4. Eisen D: The clinical manifestations and treatment of oral lichen planus. Dermatol Clin 2003, 21:79-89.
5. Olivier V, Lacour JP, Mousnier A, Garraffo R, Monteil RA, Ortonne JP: Treatment of chronic erosive oral lichen planus with low concentrations of topical tacrolimus: an open prospective study. Arch Dermatol 2002, 138:1335-1338.
6. Byrd JA, Davis MD, Bruce AJ, Drage LA, Rogers RS III: Response of oral lichen planus to topical tacrolimus in 37 patients. Arch Dermatol 20134, 140:1508-1512.
7. Morrison L, Kratochvil FJ III, Gorman A: An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol 2002, 47:617-620.
8. Hodgson TA, Sahni N, Kaliakatsou F, Buchanan JA, Porter SR: Longterm efficacy and safety of topical tacrolimus in the management of ulcerative/erosive oral lichen planus. Eur J Dermatol 2003, 13:466-470.
9. Esquivel-Pedraza L, Fernandez-Cuevas L, Ortiz-Pedroza G, Reyes-Gutierrez E, Orozco-Topete R: Treatment of oral lichen planus with topical pimecrolimus 1% cream. Br J Dermatol 2004, 150:771-773.
10. Larsson A, Warfvinge G: Malignant transformation of oral lichen planus. Oral Oncol 2003, 39:630-631.
11. Mattsson U, Jontell M, Holmstrup P: Oral lichen planus and malignant transformation: is a recall of patients justified? Crit Rev Oral Biol Med 2002, 13:390-396.
12. Euvrard S, Ulrich C, Lefrancois N: Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 2004, 30:628-633.
13. Langeland T, Engh V: Topical use of tacrolimus and squamous cell carcinoma on the penis. Br J Dermatol 2005, 152:183-185.
14. US Food and Drug Administration: FDA Public Health Advisory: Elidel (pimecrolimus) cream and Protopic (tacrolimus) ointment. [http://www.fda.gov/medwatch/SAFETY/2005/safty05.htm#Elidel]. 3-10-2005
15. Niwa Y, Terashima T, Sumi H: Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003, 149:960-967.
16. Niwa Y, Nasr I: Are we starting to induce skin cancer in order to avoid topical steroids? J Eur Acad Dermatol Venereol 2005, 19:387-389.
17. Shirane M, Nakayama KI: Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol 2003, 5:28-37.
18. Gomez-Lechon MJ, Serralta A, Donato MT, Jimenez N, O'connor E, Castell JV, Mir J: The immunosuppressant drug FK506 prevents Fas-induced apoptosis in human hepatocytes. Biochem Pharmacol 2004, 68:2427-2433.
19. Hortelano S, Lopez-Collazo E, Bosca L: Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. Br J Pharmacol 1999, 126:1139-1146.
20. Almeida S, Domingues A, Rodrigues L, Oliveira CR, Rego AC: FK506 prevents mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in rat primary cortical cultures. Neurobiol Dis 2004, 17:435-444.
21. Gold BG, Zhong YP: FK506 requires stimulation of the extracellular signal-reguiated kinase 1/2 and the steroid receptor chaperone protein p23 for neurite elongation. Neurosignals 2004, 13:122-129.
22. Zawadzka M, Kaminska B: Immunosuppressant FK506 affects multiple signaling pathways and modulates gene expression in astrocytes. Mol Cell Neurosci 2003, 22:202-209.
23. Silva LB, Van der Laan JW: Mechanisms of nongenotoxic carcinogenesis and assessment of the human hazard. Regul Toxicol Pharmacol 2000, 32:135-143.
24. Bolt HM, Foth H, Hengstler JG, Degen GH: Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective. Toxicot Lett 2004, 151:29-41.